IL2 and neoplasm: Recently, similar preclinical results were observed in renal cell carcinoma and colorectal cancer models when L19-IL-2 was co-administered with a small molecule-drug conjugate, capable of selective homing to tumor cells expressing surface carbonic anhydrase IX (63).